コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 NT Glioblastoma (GB) is the most devastating primary brain tumor.
2 rimary CNS lymphoma (PCNSL) is an aggressive primary brain tumor.
3 lastoma (GBM) is the most aggressive form of primary brain tumor.
4 the most prevalent and aggressive malignant primary brain tumor.
5 toma multiforme (GBM) is the most aggressive primary brain tumor.
6 cers including glioblastoma, the most lethal primary brain tumor.
7 orme (GBM) is the most common and aggressive primary brain tumor.
8 toma (GBM) is the most common and aggressive primary brain tumor.
9 mon, aggressive and highly malignant type of primary brain tumor.
10 strocytic tumors are the most common form of primary brain tumor.
11 (GBM), the highest grade and most aggressive primary brain tumor.
12 urvival in glioblastoma, a highly aggressive primary brain tumor.
13 ma multiforme is the most aggressive type of primary brain tumor.
14 Malignant glioma (MG) is the most lethal primary brain tumor.
15 Astrocytic tumor is the most prevalent primary brain tumor.
16 Glioblastoma multiforme (GBM) is a deadly primary brain tumor.
17 ovide insight into disease causation of this primary brain tumor.
18 e the motility-promoting role of brevican in primary brain tumors.
19 nitoring and targeting this pathway in these primary brain tumors.
20 terface, were estimated for 33 patients with primary brain tumors.
21 Astrocytomas are the most common primary brain tumors.
22 , Parkinson's disease, stroke, epilepsy, and primary brain tumors.
23 gent with a cytotoxic agent in patients with primary brain tumors.
24 entify new potential therapeutic targets for primary brain tumors.
25 genesis of oligodendrogliomas, a subtype of primary brain tumors.
26 ation, as well as in patients with untreated primary brain tumors.
27 g development, in response to injury, and in primary brain tumors.
28 gene transfer throughout highly disseminated primary brain tumors.
29 Glioblastoma (GBM) is the most lethal of primary brain tumors.
30 past, present, and future in the context of primary brain tumors.
31 studied for the treatment of peripheral and primary brain tumors.
32 ic disparities in the surgical management of primary brain tumors.
33 erapeutic opportunities to effectively treat primary brain tumors.
34 m occurs in up to one-third of patients with primary brain tumors.
35 vel insights into the pathogenesis of VTE in primary brain tumors.
36 Meningiomas account for one-third of all primary brain tumors.
37 that accounts for the majority of malignant primary brain tumors.
38 astoma multiforme (GBM), the most aggressive primary brain tumors.
39 ers to aid diagnosis and characterization of primary brain tumors.
40 understood comorbidity for individuals with primary brain tumors.
42 married, non-Hispanic white sample, 66% had primary brain tumors, 27% had brain metastases, and 8% u
44 lt glioblastoma (GBM) is a highly aggressive primary brain tumor, accounting for nearly half of all m
45 Glioblastomas (GBM) are the most prevalent primary brain tumors, affecting 5 in every 100,000 peopl
47 oblastomas are the most prevalent and lethal primary brain tumor and are comprised of hierarchies wit
49 ma (GBM) is the most prevalent and malignant primary brain tumor and contains self-renewing, tumorige
53 ma multiforme (GBM) is the most common adult primary brain tumor and is comprised of a heterogeneous
56 e, 42 [33-54] years; 154 females [55%]) with primary brain tumors and 887 transplants from them, 778
57 mas (GBMs) are the most common and malignant primary brain tumors and are aggressively treated with s
58 nt gliomas are the most frequently occurring primary brain tumors and are resistant to conventional t
59 in the field of neurology, particularly for primary brain tumors and autoimmune neurological disorde
60 opyl)-l-glutamate ((18)F-FSPG) helped detect primary brain tumors and brain metastases with a high tu
61 tumors and whole-brain irradiation, 19 with primary brain tumors and chemotherapy only, 52 with prim
62 m of brain cancer, is responsible for 23% of primary brain tumors and has extremely poor outcome.
63 lpha(v)beta(3) is frequently up-regulated in primary brain tumors and metastatic lesions of brain hom
64 ictive of outcome in children with recurrent primary brain tumors and should be evaluated as a progno
65 hanced JNK activation is frequently found in primary brain tumors and that this activation contribute
67 ed MR imaging examinations (55 patients with primary brain tumors and whole-brain irradiation, 19 wit
68 cts grouped for urgent referral, 2 confirmed primary brain tumors (and a possible but unconfirmed thi
69 tiforme (GBM) is the most aggressive type of primary brain tumor, and the presence of glioma stem cel
70 lid tumors, 50% (six of 12) of patients with primary brain tumors, and 0% (zero of nine) of patients
75 Malignant gliomas, the most common type of primary brain tumor, are a spectrum of tumors of varying
76 malignant glioma, the most lethal and common primary brain tumor, are undergoing a dramatic evolution
79 ally, examination of frozen sections from 10 primary brain tumor biopsies by immunohistochemistry rev
80 neural signaling mechanisms recapitulated in primary brain tumors, brain metastases, and solid tumors
81 acizumab is FDA-approved in the treatment of primary brain tumors, but its efficacy in patients with
82 -regulate or maintain EGFR overexpression in primary brain tumors by directly interacting with the re
83 nhanced our understanding of the genetics of primary brain tumors by uncovering several novel driver
89 rme (GBM) are aggressive and uniformly fatal primary brain tumors characterized by their diffuse inva
93 transformed mouse embryo fibroblasts and for primary brain tumor development in a rat model of neuroc
94 clude 298 children under age 20 years with a primary brain tumor diagnosed from 1984 to 1991 and 298
96 These studies demonstrate that melanomas and primary brain tumors express common MAAs and could be ex
98 ic gliomas, the most common and malignant of primary brain tumors, frequently contain activating muta
104 esions with good versus poor outcomes in the primary brain tumor group (P < .05) but not in the brain
105 Glioblastoma multiforme (GBM) is a fatal primary brain tumor harboring myriad genetic and epigene
107 Glioblastoma (GBM), the most common adult primary brain tumor, has an average survival of only 15-
112 blastoma (GBM) is the most common and lethal primary brain tumor in adults and is driven by self-rene
113 Glioblastoma is the most common form of primary brain tumor in adults and is essentially incurab
115 type (WHO grade 4) (GBM), is the most common primary brain tumor in adults with a 21-month median ove
117 e (GBM) is the most prevalent and aggressive primary brain tumor in adults, characterized by a poor p
118 toma (GBM) is the most aggressive and lethal primary brain tumor in adults, characterized by resistan
119 ients with glioma, the most common malignant primary brain tumor in adults, examination of cell-free
120 toma multiforme, the most aggressive form of primary brain tumor in adults, is nearly universally fat
121 ioblastoma is the most common and aggressive primary brain tumor in adults, with a poor prognosis bec
122 stoma (GBM) is the most aggressive malignant primary brain tumor in adults, with incidence peaking in
134 oblastoma (GBM) is the most common and fatal primary brain tumor in humans, and it is essential that
141 ress has been made in this regard for common primary brain tumors in adults, especially diffuse gliom
143 of glioblastomas, the most malignant of all primary brain tumors in adults, is responsive to TOP2 po
148 ancer survivors at risk of developing second primary brain tumors, in particular survivors of childho
150 NRP/B expression was also observed in human primary brain tumors including glioblastoma multiformae
151 n institutional phase II trial for localized primary brain tumors, including craniopharyngioma, epend
152 er factor (HGF/SF) and Met staining in human primary brain tumors increases with the grade of maligna
153 In conclusion, high podoplanin expression in primary brain tumors induces platelet aggregation, corre
154 of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more signif
155 a, the most aggressive and prevalent form of primary brain tumor, is characterized by rapid growth, d
157 Glioblastoma, the most malignant type of primary brain tumor, is one of the solid cancers where c
159 especially in indications such as gliomas, a primary brain tumor known for resistance to any immune i
161 analysis of 300 meningiomas, the most common primary brain tumors, leading to the discovery of mutati
165 s: healthy brain (nonhuman primates (NHPs)), primary brain tumors (mouse glioblastoma), and metastati
166 ents (GBCAs) form the cornerstone of current primary brain tumor MRI protocols at all stages of the p
167 he nucleus of normal brain cells, whereas in primary brain tumors NRP/B was almost exclusively contai
169 ts use as a diagnostic marker to distinguish primary brain tumors of similar histology but different
175 persomnolence, is a core symptom reported by primary brain tumor patients and often manifests after r
177 been used in the evaluation of patients with primary brain tumors (PBTs), but so far series have repo
179 pramolecular hydrogel effectively suppresses primary brain tumor recurrence and prolongs overall surv
180 was performed on 27 children with recurrent primary brain tumors referred to our institution for inv
182 multiforme (GBM), the most common malignant primary brain tumor, represents a significant disease bu
184 analysis demonstrated that 86% (18 of 21) of primary brain tumors showed evidence of JNK activation b
191 This article reviews the classification of primary brain tumors, the histologic changes associated
193 ials using novel agents for the treatment of primary brain tumors, there have been few advances that
194 has been shown to be frequently activated in primary brain tumors, to enhance several tumorigenic phe
195 els in individual cells in sections from 167 primary brain tumors treated with BCNU were quantitated
196 Glioblastoma, the most common and aggressive primary brain tumor type, is considered an immunological
197 e glycoprotein, increases the risk of VTE in primary brain tumors via its ability to induce platelet
199 he expression of NRP/B mutants isolated from primary brain tumors was found in the cytoplasm, and the
200 ion in transplants from deceased donors with primary brain tumors was lower than previously thought,
201 ion of these gene-inactivation mechanisms in primary brain tumors, we integrated RLGS-based methylati
204 e (MR) images in a cohort of patients with a primary brain tumor who had not received linear gadolini
212 lioblastoma (GBM) is an aggressive malignant primary brain tumor with limited therapeutic options.
213 ltiforme (GBM) is the most common and lethal primary brain tumor with median survival of only 12 to 1
214 ifome is the most common and most aggressive primary brain tumor with no current curative therapy.
218 f dying as a result of the transmission of a primary brain tumor with the risks of dying if not trans
220 Glioblastomas (GBMs) are the most aggressive primary brain tumors, with an average survival of less t
221 brain tumors and chemotherapy only, 52 with primary brain tumors without any treatment, and 18 with